Version: 1.0.0 | Published: 8 Jan 2026 | Updated: 51 days ago
Documentation
Description:
CASPS is a multicentre, double-blind, placebo-controlled, randomised, phase 2 trial. 48 participants were randomly assigned (2:1) to either cediranib (30 mg orally, once daily) or matching placebo tablets for 24 weeks. Participants were unblinded at week 24 or sooner if they had progression; those on placebo crossed over to cediranib and all participants continued on treatment until progression or death.
Clinical data and sample collection.
Coverage
Spatial:
United Kingdom, Spain, Australia
Follow Up:
1 - 10 Years
Provenance
Temporal
Accrual Periodicity:
Static
Start Date:
31 May 2019
Time Lag:
Not applicable
Accessibility
Access
Access Rights:
Please contact the publisher using Contact Point details provided
Access Request Cost:
Not specified
Delivery Lead Time:
Other
Jurisdictions:
UK
Data Controller:
The Institute of Cancer Research
Data Processor:
The Institute of Cancer Research
Format and Standards
Vocabulary Encoding Schemes:
LOCAL
Conforms To:
LOCAL
Languages:
en
Formats:
In Progress